Seladelpar

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Seladelpar
Seladelpar.svg
Clinical data
SynonymsMBX-8025; RWJ-800025
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC21H23F3O5S
Molar mass444.465 g/mol g·mol−1
3D model (JSmol)

Seladelpar (INN, USAN; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex.[1][2][3] According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV.[4]

See also[edit]

References[edit]

  1. ^ "Seladelpar - CymaBay Therapeutics - AdisInsight".
  2. ^ Billin, A. N. (2008). "PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: An adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307.
  3. ^ Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK (September 2011). "MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin". J. Clin. Endocrinol. Metab. 96 (9): 2889–97. doi:10.1210/jc.2011-1061. PMID 21752880.
  4. ^ "Targeting Mixed Dyslipidemia and Metabolic Syndrome". Archived from the original on 2006-10-17.

External links[edit]